CARLSBAD, Calif., Feb. 15, 2017 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will
host a live webcast on Tuesday, February
28 at 11:30 a.m. Eastern Time
to discuss its 2016 financial results and report on pipeline and
business progress.
Interested parties may listen to the call by dialing
877-443-5662 or access the webcast at www.ionispharma.com. A
webcast replay will be available for a limited time at the same
address.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases.
Using its proprietary antisense technology, Ionis has created a
large pipeline of first-in-class or best-in-class drugs, with over
three dozen drugs in development. SPINRAZA™ (nusinersen) is a drug
that has been approved in the U.S. for the treatment of spinal
muscular atrophy (SMA) in pediatric and adult patients.
Biogen is responsible for commercialization of SPINRAZA.
Drugs currently in Phase 3 development include volanesorsen, a drug
Ionis is developing and plans to commercialize through its wholly
owned subsidiary, Akcea Therapeutics, to treat patients with either
familial chylomicronemia syndrome or familial partial
lipodystrophy; and IONIS-TTRRx, a drug Ionis is
developing with GSK to treat patients with TTR amyloidosis.
Ionis' patents provide strong and extensive protection for
its drugs and technology. Additional information about Ionis
is available at www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding Ionis
Pharmaceuticals' financial position and outlook, Ionis' business,
the business of Akcea Therapeutics, Inc., a subsidiary of Ionis
Pharmaceuticals, and the therapeutic and commercial potential of
Ionis' technologies and products in development, including
SPINRAZA, IONIS-TTRRx and volanesorsen. Any
statement describing Ionis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a
business around such drugs. Ionis' forward-looking statements
also involve assumptions that, if they never materialize or prove
correct, could cause its results to differ materially from those
expressed or implied by such forward-looking statements.
Although Ionis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Ionis. As a result, you
are cautioned not to rely on these forward-looking
statements. These and other risks concerning Ionis' programs
are described in additional detail in Ionis' annual report on Form
10-K for the year ended December 31,
2015, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other
documents are available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis
Pharmaceuticals, Inc. SPINRAZA™ is a trademark of Biogen.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-hold-2016-financial-results-conference-call-300407421.html
SOURCE Ionis Pharmaceuticals, Inc.